Intra-articular Lopain (MTX-071) Phase I/IIa Study in Chronic Osteoarthritic Knee Joint Pain

Phase 1

Completed

• Conditions: Osteoarthritis, Knee
• Interventions: Drug: Lopain

• Registration Number: NCT02566564
• Lead Sponsor: Grünenthal GmbH

Brief Summary

Phase I/IIa study to determine the safety and clinical effects of intra-articular injections of MTX-071 (Lopain) in patients with chronic osteoarthritic knee-joint pain.

Detailed Description

Open label, single-dose, dose-escalating phase I/IIa study to determine the safety and clinical effects of intra-articular injections of MTX-071 (Lopain) in patients with chronic osteoarthritic knee-joint pain.

Study Timeline

• Study First Submitted: 2015-09-22
• Study First Submitted QC: 2015-10-01
• Study First Posted: 2015-10-02
• Study Start: 2016-04
• Primary Completion: 2017-06
• Study Completion: 2017-06
• Status Verified: 2021-07
• Last Update Submitted: 2021-07-12
• Last Update Posted: 2021-07-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

• Written informed consent
• Written informed consent
• Men or women aged between 40 and 70 years
• At least 40 mm on motion and at least 10 mm at rest on the 100 mm-VAS (Visual Analog Scale) for average arthritic joint pain in the knee to be studied during the last 2 days, with or without pain medication.
• Previously documented radiography showing a Kellgren Lawrence Grade 2 - 4 severity.
• Female patients of childbearing potential or female partners of childbearing potential of male patients must agree to use a reliable contraceptive method for at least one month after the injection of MTX-071.
• Subject is highly likely to comply with the protocol and complete the study.

Exclusion Criteria

• Knee surgery within 6 months before study start or planned for any time during the next 6 months.
• Any injection into the knee to be studied within the preceding 7 days or trauma to the knee not yet healed.
• History of any clinically significant cardiac, renal, and/or other relevant disease or malignancy.
• History of severe allergic or anaphylactic reactions.
• Pregnancy.
• Major bleeding disorder.
• Clinically significant deviation from the normal laboratory values.
• Clinically significant abnormal ECG
• History of clinically relevant drug/chemical/ substance/alcohol abuse within the past 2 years prior to screening.
• Symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within the past 2 weeks prior to study medication administration.
• Patients positive for human immunodeficiency virus (HIV) antibody, hepatitis C antibody, or for hepatitis B virus surface antigen (HBsAg), tuberculosis.
• Patients who had a corticosteroid injection in the knee to be studied within 3 months prior to baseline or are planned to get a corticosteroid injection within 4 weeks following the injection of MTX-071.
• Vaccination within 60 days prior to study medication administration.
• Systemic immunosuppressant agent within 6 months prior to study medication administration
• Experimental agent within 30 days or ten half-lives, whichever is longer, prior to study medication administration.
• Any other condition, which in the opinion of the investigator, precludes the subject's participation in the trial.
• Patients who are dependent on the sponsor or investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
open label, single arm	Lopain	Open label, single arm, dose escalating

Primary Outcome Measures

Name	Time	Method
Intensity and severity of AES/SAEs potentially causally related with the study medication	up to 6 months	overall and per dose level (descriptive statistics) incidence, intensity and severity of AES/SAEs potentially causally related with the study medication

Secondary Outcome Measures

Name	Time	Method
Acceptance of / satisfaction with treatment as stated by the patients and physicians. (VAS score)	up to 6 months	per dose level VAS score on acceptance of / satisfaction with treatment as stated by the patients and physicians.
duration of pain relief response: overall and dose response	up to 6 months	overall and per dose level intra-patients maintenance at 7 days, 1, 3 and 6 months of the pain relief response defined as more than a 20% decrease from baseline in mm on the VAS for pain on motion without increase in pain medication
pain relief response: overall and dose response	up to 6 months	overall and per dose level percentage of patients overall percentage of patients with pain relief response to single intraarticular administration of Lopain (MTX-071) defined as more than a 20% decrease from baseline in mm on the VAS for pain on motion without increase in pain medication
Influence of treatment on functionality of the knee joint and patients' general feeling of health and estimation of daily life conditions (VAS scores)	up to 6 months	per dose level VAS scores on functionality of the knee joint and patients' general feeling of health and estimation of daily life conditions

Trial Locations

Locations (1)

SGS Antwerpen; 🇧🇪 Antwerpen, Belgium